The biopharmaceutical industry’s positive regulatory momentum carried on through 2019, despite an early-year government shutdown, a data manipulation scandal around a high-profile approval, and many months without permanent leadership at the FDA.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. Fresh from the biotech pipeline—2019. Nat Biotechnol 38, 126–131 (2020). https://doi.org/10.1038/s41587-019-0405-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0405-7
- Springer Nature America, Inc.
This article is cited by
-
Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products
Pharmaceutical Research (2021)
-
Simultaneous development of zanubrutinib in the USA and China
Nature Reviews Clinical Oncology (2020)
-
Translating academic careers into industry healthcare professions
Nature Biotechnology (2020)